drugset / Trial / NCT03936218
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2023-11-30
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goserelin | Other / unclassified | 10.8 mg | Subcutaneous |